Clinical Trial Search

Primary: Change From Baseline in Trough FEV1 at Treatment Visit Day 7 Compared to Placebo. — -0.0282; -0.0156; 0.0540; 0.0806 liters — p=0.9730

Primary: Headache Pain Relief at 2 hr — 40; 62; 58; 68 Participants — p=0.0012

Primary: Headache Pain Relief at 2 hr Post-dose by 2-point Definition — 6; 11; 13 Participants

Primary: AUC(0-inf) of GP2013, MabThera and Rituxan Following IV Infusion in Patients With RA — 7627.44; 6896.97; 7536.89 day*mcg/mL

Primary: Number of Participants With Respiratory and/or Hemodynamic Deteriorations — 1; 3 Participants

Primary: Percentage of Clinical Responders at 4-week Follow-up — 15; 12; 24; 26 Participants

Primary: Morning Pre-dose Trough FEV1 — 0.101; 0.098; 0.077; -0.031 Liters

Primary: Change From Baseline to Endpoint (Week 13/Early Termination) in Pruritus — -1.470; -1.486; -0.620; -0.580 Score on a scale — p=0.0321

Primary: Objective Remission Rate — 18.8 percentage of participants

Primary: Change From Baseline to Week 16 in Pulmonary Vascular Resistance (PVR) at Rest. — 73.0; 87.2 percent of baseline PVR — p=0.0410

Primary: Response Rate = Complete and Partial Response at 12 Weeks. — 5; 3; 2; 15 participants

Primary: Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of Ixazomib (Phase 1) — 3; 4; 3; 4 mg

Primary: Overall Response at 6 Months — 0; 0; 7; 9 Participants

Primary: Change in HbA1c (Glycosylated Haemoglobin) — -0.97; -1.30; -1.65; -1.96 percentage of glycosylated haemoglobin — p=<0.0001

Primary: Intra-individual Difference in Reepithelialization of Wound (Halves) at Day 14 in 'Recent Wounds' or Day 28 in 'Chronic Wounds' — 8; 0 Wounds — p==0.008